PRALUZATAMAB

UNII:	X7F47LV4T7
Formula:
Preferred Substance Name:	PRALUZATAMAB
GSRS Full Record:	X7F47LV4T7 i

2145109-70-0
ANTI-CD166 PROBODY-DRUG
CX-191
IMMUNOGLOBULIN G1, ANTI-(HUMAN ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE) (HUMAN MONOCLONAL CX-191 .GAMMA.1-CHAIN), DISULFIDE WITH PRODOMAIN PROTEIN (SYNTHETIC MASKING MOIETY AND CLEAVABLE MOIETY PROTEASE SUBSTRATE-CONTAINING) FUSION PROTEIN WITH HUMAN MONOCLONAL CX-191 .KAPPA.-CHAIN, DIMER
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD166 (ACTIVATED LEUCOCYTE CELL ADHESION MOLECULE, ALCAM)), HUMANIZED MONOCLONAL ANTIBODY
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD166 ANTIGEN (ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE)); HUMANIZED MONOCLONAL ANTIBODY; .GAMMA.1 HEAVY CHAIN HUMANIZED (1-450) (VH (HOMO SAPIENS IGHV2-5*01 (89%) (IGHD)-IGHJ4*01 (93%)) (10.7.13) (1-121)-HOMO SAPIENS IGHG1*03 (CH1(R97>K(217)), CH3(K107>DEL(451))) (122-450)), (224-270')-DISULFIDE WITH .KAPPA. LIGHT CHAIN HUMANIZED (1'-270') (N-TERMINAL REGION (SYNTHETIC MASKING MOIETY-(1'-22')-TRIGLYCYLDISERYLDIGLYCYLSERYL LINKER-(23'-30')-CLEAVABLE MOIETY PROTEASE SUBSTRATE-CONTAINING-(31'-48')-DIGLYCYLSERYL LINKER (49'-51')))-(1'-51')-(HUMANIZED V-KAPPA (MUS MUSCULUS IGKV2-109*01 (91%) IGKJ2*03 (92%):HOMO SAPIENS IGKV2-28*01 (89%) IGKJ2*01)-(11.3.9) (52'-163')-HOMO SAPIENS IGKC*01 (164'-270')), DIMER (230-230'':233-233'')-BISDISULFIDE
PRALUZATAMAB [INN]
PRALUZATAMAB [USAN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

PRALUZATAMAB

Synonyms and Mappings

Resources